ArticleBMC gastroenterology2025
The diagnostic value of serum cysteine protease inhibitor (CST4) in colorectal cancer: a preliminary study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCST4 is associated with various cancers but its diagnostic value in colorectal cancer (CRC) has not been clearly established. This study aims to further validate the diagnostic value of CST4 in colorectal cancer using random forest models in machine learning based on existing research.
methodsFirst, the expression of CST4 in CRC patients is analyzed using data from The Cancer Genome Atlas (TCGA) and the results show that CST4 is significantly high expression in CRC patients. To further investigate the diagnostic value of CST4, this retrospective study include 59 colorectal cancer patients, 51 patients with colorectal precancerous lesions and 40 patients with non-adenomatous polyps who visited Chaohu Hospital Affiliated to Anhui Medical University from August 2022 to September 2023. Their serum was collected and the CST4 level was detected by the double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) method. At the same time, CEA and CA199 were also tested.
resultsAnalysis of the TCGA database show that CST4 is significantly over expressed in colorectal cancer tissues, including colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ). Serum tests confirm that CST4 levels in CRC patients are significantly higher than those in the precancerous lesion and the polyp group (P < 0.001). However, no significant difference is observed between the precancerous lesion and polyp group. In the ROC curve, the area under the curve (AUC) of CST4 is 0.768 in the CRC group versus the precancerous lesion group and 0.769 in the CRC group versus the polyp group, which is significantly higher than that of CEA (AUC = 0.651/0.659) and CA199 (AUC = 0.486/0.601). In the diagnostic model constructed based on CST4, CEA and CA199, CST4 has the highest weight in differentiating CRC, further confirming its diagnostic value.
conclusionThe study indicates that CST4 has a higher diagnostic value in colorectal cancer (CRC) and CST4 provides a new approach for early clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.